VIASKIN Peanut Emerging Drug Insight and Market Forecast – 2032

VIASKIN Peanut Emerging Drug Insight and Market Forecast – 2032

“VIASKIN Peanut Emerging Drug Insight and Market Forecast – 2032” report provides comprehensive insights about VIASKIN Peanut for Food Allergy in the 7MM. A detailed picture of the VIASKIN Peanut for Food Allergy in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the VIASKIN Peanut for Food Allergy. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the VIASKIN Peanut market forecast, analysis for Food Allergy in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about emerging therapies in Food Allergy.

Drug Summary

VIASKIN Peanut is the first Epicutaneous Immunotherapy (EPIT) in development that leverages the skin to activate the immune system and induce desensitization in peanut-allergic children.

EPIT aims to target specific epidermal dendritic cells, called Langerhans cells. Pre-clinical research has shown that these cells capture antigens and migrate to the lymph node in order to activate the immune system. By delivering the allergen directly to the lymph node through the Langerhans cells, pre-clinical research has shown that EPIT activates specific regulatory T cells (Tregs) that can down-regulate the Th2-oriented reaction to the allergen (VIASKIN Peanut, 2018).

The drug is being developed for three different age groups. The trials for age groups 1–3 are in Phase III. The trials for age groups 4–11 are also in Phase III, whereas the trials for adolescents and adults have completed Phase II and are being planned for Phase III.

Scope of the Report

The report provides insights into:

A comprehensive product overview including the VIASKIN Peanut description, mechanism of action, dosage and administration, research and development activities in Food Allergy.

Elaborated details on VIASKIN Peanut regulatory milestones and other development activities have been provided in this report.

The report also highlights the VIASKIN Peanut research and development activity in Food Allergy details across the United States, Europe and Japan.

The report also covers the patents information with expiry timeline around VIASKIN Peanut.

The report contains forecasted sales of VIASKIN Peanut for Food Allergy till 2032.

Comprehensive coverage of the late-stage emerging therapies for Food Allergy.

The report also features the SWOT analysis with analyst views for VIASKIN Peanut in Food Allergy.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

VIASKIN Peanut Analytical Perspective by DelveInsight

In-depth VIASKIN Peanut Market Assessment

This report provides a detailed market assessment of VIASKIN Peanut in Food Allergy in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2022 to 2032.

VIASKIN Peanut Clinical Assessment

The report provides the clinical trials information of VIASKIN Peanut for Food Allergy covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

In the coming years, the market scenario for Food Allergy is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence VIASKIN Peanut dominance.

Other emerging products for Food Allergy are expected to give tough market competition to VIASKIN Peanut and launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of VIASKIN Peanut in Food Allergy.

Our in-depth analysis of the forecasted sales data of VIASKIN Peanut from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the VIASKIN Peanut in Food Allergy.

Key Questions

What is the product type, route of administration and mechanism of action of VIASKIN Peanut?

What is the clinical trial status of the study related to VIASKIN Peanut in Food Allergy and study completion date?

What are the key collaborations, mergers and acquisitions, licensing and other activities related to the VIASKIN Peanut development?

What are the key designations that have been granted to VIASKIN Peanut for Food Allergy?

What is the forecasted market scenario of VIASKIN Peanut for Food Allergy?

What are the forecasted sales of VIASKIN Peanut in the 7MM, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?

What are the other emerging products available in Food Allergy and how are they giving competition to VIASKIN Peanut for Food Allergy?

Which are the late-stage emerging therapies under development for the treatment of Food Allergy?